In conclusion, our study describes the incidence of KRAS mutations in a multicenter, real-world CRC cohort with similar clinicopathological features as reported in the literature and describes, for the first time, the clinicopathological characteristics of CRCs harboring Gly12Asp mutations, providing novel insights into their potential biological behavior. This evidence concerns the gene KRAS and colorectal carcinoma.